CD274 and T-cell non-Hodgkin lymphoma: Extranodal natural killer (NK)/T-cell lymphoma (ENKTL) responds to pembrolizumab because the integration of the Epstein–Barr virus (EBV) in tumor cells can induce PD-L1 expression [7,8].